NASDAQ:BLUE bluebird bio - BLUE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.73 +0.07 (+1.05%) (As of 02/7/2023 09:38 AM ET) Add Compare Share Share Today's Range$6.58▼$6.7450-Day Range$5.92▼$8.4952-Week Range$2.87▼$8.58Volume69,354 shsAverage Volume4.03 million shsMarket Capitalization$558.05 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media bluebird bio MarketRank™ ForecastAnalyst RatingHold1.89 Rating ScoreUpside/Downside1.4% Upside$6.75 Price TargetShort InterestBearish22.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$62,595 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.39) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.21 out of 5 starsMedical Sector998th out of 1,027 stocksBiological Products, Except Diagnostic Industry166th out of 169 stocks 0.9 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 1.89, and is based on 1 buy rating, 6 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.75, bluebird bio has a forecasted upside of 1.4% from its current price of $6.66.Amount of Analyst Coveragebluebird bio has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.25% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in bluebird bio has recently increased by 1.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 3.3 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for bluebird bio this week, compared to 4 articles on an average week.Search Interest23 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat Follows10 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,595.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions79.01% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($4.39) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About bluebird bio (NASDAQ:BLUE) Stockbluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.Read More Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Stock News HeadlinesFebruary 3, 2023 | finance.yahoo.comHere's why 2seventy bio's chief executive thinks 2023 will be a 'special year'January 30, 2023 | finance.yahoo.combluebird bio, Inc. (NASDAQ:BLUE) is favoured by institutional owners who hold 58% of the companyFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 30, 2023 | marketwatch.comAdvanced Therapy Medicinal Products Industry by 360 Market Updates with, New Companies, Major Strategies, Massive Strategies And Forecast 2028January 28, 2023 | nasdaq.comBlackRock Inc. Increases Position in bluebird bio Inc (BLUE)January 27, 2023 | seekingalpha.combluebird bio: More Share Dilution LikelyJanuary 24, 2023 | msn.comWhy are new drugs so expensive?January 23, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Bluebird Bio (BLUE)February 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 19, 2023 | markets.businessinsider.comBluebird Bio Prices Public Offering Of 20 Mln Shares At $6.00/shrJanuary 18, 2023 | finance.yahoo.combluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common StockJanuary 18, 2023 | marketwatch.comBluebird Bio Begins Public Offering of 20 Million SharesJanuary 18, 2023 | finance.yahoo.combluebird bio, Inc. Announces Proposed Public Offering of Common StockJanuary 12, 2023 | marketwatch.comSickle Cell Disease Treatments Market Future Trends Demand 2023, and Forecast to 2028January 9, 2023 | benzinga.comSickle Cell Disease Treatment Market Size to Surpass Around USD 8.75 Billion by 2029 | Research Report by Fortune Business InsightsJanuary 9, 2023 | finance.yahoo.combluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and Humana (HUM)January 6, 2023 | markets.businessinsider.comBluebird Bio Announces Sale Of Second Rare Pediatric Disease Priority Review Voucher For $95 MlnJanuary 6, 2023 | finance.yahoo.combluebird bio Sells Second Priority Review Voucher for $95 MillionJanuary 5, 2023 | benzinga.comNewly Approved Drugs In US Command Over $200,000 On An AverageJanuary 5, 2023 | finance.yahoo.combluebird bio to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.combluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal OfficerDecember 28, 2022 | seekingalpha.comBLUE bluebird bio, Inc.December 26, 2022 | finance.yahoo.comDrug Prices Reach New High—in the MillionsDecember 21, 2022 | finance.yahoo.comImplied Volatility Surging for bluebird bio (BLUE) Stock OptionsDecember 19, 2022 | finance.yahoo.comFDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed ProtocolDecember 19, 2022 | benzinga.comFDA Lifts Partial Clinical Hold for bluebird bio's Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Company Calendar Last Earnings11/05/2021Today2/07/2023Next Earnings (Estimated)3/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees518Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.75 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+0.3%Consensus RatingHold Rating Score (0-4)1.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($6.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-819,380,000.00 Net Margins-8,828.28% Pretax Margin-8,384.38% Return on Equity-173.58% Return on Assets-77.81% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual Sales$3.66 million Price / Sales152.47 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book1.26Miscellaneous Outstanding Shares82,920,000Free Float81,099,000Market Cap$558.05 million OptionableOptionable Beta0.92 Key ExecutivesAndrew ObenshainPresident, Chief Executive Officer & DirectorThomas J. KlimaChief Operating & Commercial OfficerChristopher Stanley KrawtschukTreasurer, Chief Financial & Accounting OfficerRichard ColvinChief Medical OfficerMelissa BonnerSenior Vice President-ResearchKey CompetitorsMesoblastNASDAQ:MESONanoString TechnologiesNASDAQ:NSTGCullinan OncologyNASDAQ:CGEMCompass TherapeuticsNASDAQ:CMPXAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCBought 126,218 shares on 2/6/2023Ownership: 0.152%Daiwa Securities Group Inc.Bought 7,354 shares on 2/6/2023Ownership: 0.009%Monaco Asset Management SAMSold 30,000 shares on 2/3/2023Ownership: 0.060%SG Americas Securities LLCBought 6,140 shares on 2/2/2023Ownership: 0.029%ProShare Advisors LLCBought 2,538 shares on 2/2/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions BLUE Stock - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price forecast for 2023? 9 analysts have issued 12 month price targets for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they expect the company's share price to reach $6.75 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2023? bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE stock has decreased by 3.8% and is now trading at $6.66. View the best growth stocks for 2023 here. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing analysts' consensus estimates of ($2.65) by $0.51. The biotechnology company earned $22.70 million during the quarter, compared to analysts' expectations of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 173.58% and a negative net margin of 8,828.28%. The business's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the firm posted ($2.94) earnings per share. What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). What is bluebird bio's stock symbol? bluebird bio trades on the NASDAQ under the ticker symbol "BLUE." Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Los Angeles Capital Management LLC (0.15%), Hennion & Walsh Asset Management Inc. (0.12%), Monaco Asset Management SAM (0.06%), Monaco Asset Management SAM (0.06%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is bluebird bio's stock price today? One share of BLUE stock can currently be purchased for approximately $6.66. How much money does bluebird bio make? bluebird bio (NASDAQ:BLUE) has a market capitalization of $552.25 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis. How many employees does bluebird bio have? The company employs 518 workers across the globe. How can I contact bluebird bio? bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com. This page (NASDAQ:BLUE) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.